Skip to main content
padlock icon - secure page this page is secure

Allogeneic hematopoietic stem cell transplantation in r/r Hodgkin lymphoma after treatment with checkpoint inhibitors: Feasibility and safety

Buy Article:

$59.00 + tax (Refund Policy)

Relapsed cHL patients after autologous hematopoietic stem cell transplantation (HSCT) with treatment‐sensitive disease are potential candidates for curative allogeneic HSCT. However, there are some concerns around performing such procedure after checkpoint inhibitors (CPIs).
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Hodgkin lymphoma; Nivolumab; Pembrolizumab; allogeneic transplantation; checkpoint inhibitor

Document Type: Research Article

Publication date: February 1, 2019

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more